Cargando…

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming incr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tea, Fiona, Lopez, Joseph A., Ramanathan, Sudarshini, Merheb, Vera, Lee, Fiona X. Z., Zou, Alicia, Pilli, Deepti, Patrick, Ellis, van der Walt, Anneke, Monif, Mastura, Tantsis, Esther M., Yiu, Eppie M., Vucic, Steve, Henderson, Andrew P. D., Fok, Anthony, Fraser, Clare L., Lechner-Scott, Jeanette, Reddel, Stephen W., Broadley, Simon, Barnett, Michael H., Brown, David A., Lunemann, Jan D., Dale, Russell C., Brilot, Fabienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724269/
https://www.ncbi.nlm.nih.gov/pubmed/31481127
http://dx.doi.org/10.1186/s40478-019-0786-3
_version_ 1783448954680115200
author Tea, Fiona
Lopez, Joseph A.
Ramanathan, Sudarshini
Merheb, Vera
Lee, Fiona X. Z.
Zou, Alicia
Pilli, Deepti
Patrick, Ellis
van der Walt, Anneke
Monif, Mastura
Tantsis, Esther M.
Yiu, Eppie M.
Vucic, Steve
Henderson, Andrew P. D.
Fok, Anthony
Fraser, Clare L.
Lechner-Scott, Jeanette
Reddel, Stephen W.
Broadley, Simon
Barnett, Michael H.
Brown, David A.
Lunemann, Jan D.
Dale, Russell C.
Brilot, Fabienne
author_facet Tea, Fiona
Lopez, Joseph A.
Ramanathan, Sudarshini
Merheb, Vera
Lee, Fiona X. Z.
Zou, Alicia
Pilli, Deepti
Patrick, Ellis
van der Walt, Anneke
Monif, Mastura
Tantsis, Esther M.
Yiu, Eppie M.
Vucic, Steve
Henderson, Andrew P. D.
Fok, Anthony
Fraser, Clare L.
Lechner-Scott, Jeanette
Reddel, Stephen W.
Broadley, Simon
Barnett, Michael H.
Brown, David A.
Lunemann, Jan D.
Dale, Russell C.
Brilot, Fabienne
author_sort Tea, Fiona
collection PubMed
description Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming increasingly clear as therapeutic and prognostic differences from multiple sclerosis are acknowledged, an in-depth characterization of human MOG Ab is required to answer key challenges in patient diagnosis, treatment, and prognosis. Herein, we investigated the epitope, binding sensitivity, and affinity of MOG Ab in a cohort of 139 and 148 MOG antibody-seropositive children and adults (n = 287 patients at baseline, 130 longitudinal samples, and 22 cerebrospinal fluid samples). MOG extracellular domain was also immobilized to determine the affinity of MOG Ab. MOG Ab response was of immunoglobulin G1 isotype, and was of peripheral rather than intrathecal origin. High affinity MOG Ab were detected in 15% paediatric and 18% adult sera. More than 75% of paediatric and adult MOG Ab targeted a dominant extracellular antigenic region around Proline42. MOG Ab titers fluctuated over the progression of disease, but affinity and reactivity to Proline42 remained stable. Adults with a relapsing course intrinsically presented with a reduced immunoreactivity to Proline42 and had a more diverse MOG Ab response, a feature that may be harnessed for predicting relapse. Higher titers of MOG Ab were observed in more severe phenotypes and during active disease, supporting the pathogenic role of MOG Ab. Loss of MOG Ab seropositivity was observed upon conformational changes to MOG, and this greatly impacted the sensitivity of the detection of relapsing disorders, largely considered as more severe. Careful consideration of the binding characteristics of autoantigens should be taken into account when detecting disease-relevant autoantibodies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-019-0786-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6724269
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67242692019-09-10 Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination Tea, Fiona Lopez, Joseph A. Ramanathan, Sudarshini Merheb, Vera Lee, Fiona X. Z. Zou, Alicia Pilli, Deepti Patrick, Ellis van der Walt, Anneke Monif, Mastura Tantsis, Esther M. Yiu, Eppie M. Vucic, Steve Henderson, Andrew P. D. Fok, Anthony Fraser, Clare L. Lechner-Scott, Jeanette Reddel, Stephen W. Broadley, Simon Barnett, Michael H. Brown, David A. Lunemann, Jan D. Dale, Russell C. Brilot, Fabienne Acta Neuropathol Commun Research Over recent years, human autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG Ab) have been associated with monophasic and relapsing central nervous system demyelination involving the optic nerves, spinal cord, and brain. While the clinical relevance of MOG Ab detection is becoming increasingly clear as therapeutic and prognostic differences from multiple sclerosis are acknowledged, an in-depth characterization of human MOG Ab is required to answer key challenges in patient diagnosis, treatment, and prognosis. Herein, we investigated the epitope, binding sensitivity, and affinity of MOG Ab in a cohort of 139 and 148 MOG antibody-seropositive children and adults (n = 287 patients at baseline, 130 longitudinal samples, and 22 cerebrospinal fluid samples). MOG extracellular domain was also immobilized to determine the affinity of MOG Ab. MOG Ab response was of immunoglobulin G1 isotype, and was of peripheral rather than intrathecal origin. High affinity MOG Ab were detected in 15% paediatric and 18% adult sera. More than 75% of paediatric and adult MOG Ab targeted a dominant extracellular antigenic region around Proline42. MOG Ab titers fluctuated over the progression of disease, but affinity and reactivity to Proline42 remained stable. Adults with a relapsing course intrinsically presented with a reduced immunoreactivity to Proline42 and had a more diverse MOG Ab response, a feature that may be harnessed for predicting relapse. Higher titers of MOG Ab were observed in more severe phenotypes and during active disease, supporting the pathogenic role of MOG Ab. Loss of MOG Ab seropositivity was observed upon conformational changes to MOG, and this greatly impacted the sensitivity of the detection of relapsing disorders, largely considered as more severe. Careful consideration of the binding characteristics of autoantigens should be taken into account when detecting disease-relevant autoantibodies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40478-019-0786-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-03 /pmc/articles/PMC6724269/ /pubmed/31481127 http://dx.doi.org/10.1186/s40478-019-0786-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tea, Fiona
Lopez, Joseph A.
Ramanathan, Sudarshini
Merheb, Vera
Lee, Fiona X. Z.
Zou, Alicia
Pilli, Deepti
Patrick, Ellis
van der Walt, Anneke
Monif, Mastura
Tantsis, Esther M.
Yiu, Eppie M.
Vucic, Steve
Henderson, Andrew P. D.
Fok, Anthony
Fraser, Clare L.
Lechner-Scott, Jeanette
Reddel, Stephen W.
Broadley, Simon
Barnett, Michael H.
Brown, David A.
Lunemann, Jan D.
Dale, Russell C.
Brilot, Fabienne
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title_full Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title_fullStr Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title_full_unstemmed Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title_short Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
title_sort characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724269/
https://www.ncbi.nlm.nih.gov/pubmed/31481127
http://dx.doi.org/10.1186/s40478-019-0786-3
work_keys_str_mv AT teafiona characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT lopezjosepha characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT ramanathansudarshini characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT merhebvera characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT leefionaxz characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT zoualicia characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT pillideepti characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT patrickellis characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT vanderwaltanneke characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT monifmastura characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT tantsisestherm characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT yiueppiem characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT vucicsteve characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT hendersonandrewpd characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT fokanthony characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT fraserclarel characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT lechnerscottjeanette characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT reddelstephenw characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT broadleysimon characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT barnettmichaelh characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT browndavida characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT lunemannjand characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT dalerussellc characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT brilotfabienne characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination
AT characterizationofthehumanmyelinoligodendrocyteglycoproteinantibodyresponseindemyelination